Search research articles
Contact Us
Filters
Showing results (11-20 of 311) with videos related to
Page
of 32
Sort By:
European Urology Oncology
|
July 7, 2022
Managing Prostate Cancer Recurrence After Local Treatment: Balancing Benefits Against Risks in a Rapidly Changing Environment
Bertrand Tombal
European Urology
|
January 2, 2014
Re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30
Bertrand Tombal
European Urology
|
March 19, 2011
Words of Wisdom. Re: pharmacological prevention of side effects of androgen deprivation therapy, a new challenge?
Bertrand Tombal
BJU International
|
February 25, 2012
New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist
Bertrand Tombal
European Urology
|
October 8, 2008
Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth
Bertrand Tombal
European Journal of Cancer (Oxford, England : 1990)
|
September 28, 2011
What is the pathophysiology of a hormone-resistant prostate tumour?
Bertrand Tombal
European Urology
|
September 24, 2011
Hormone therapy for prostate cancer: what have we done with Charles Huggins' legacy?
Bertrand Tombal
Urologia Internationalis
|
December 10, 2009
A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient
Bertrand Tombal
European Urology
|
August 9, 2012
Toward the end of blind prostate biopsies?
Bertrand Tombal
European Urology
|
December 18, 2013
Castration-resistant prostate cancer: adaptation or clonal selection? Insight from the EORTC 30891 trial
Bertrand Tombal
Page
of 32
Search research articles
Search
Showing results (11-20 of 311) with videos related to
Sort By:
Page
of 32
European Urology Oncology
|
July 7, 2022
Managing Prostate Cancer Recurrence After Local Treatment: Balancing Benefits Against Risks in a Rapidly Changing Environment
Bertrand Tombal
European Urology
|
January 2, 2014
Re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30
Bertrand Tombal
European Urology
|
March 19, 2011
Words of Wisdom. Re: pharmacological prevention of side effects of androgen deprivation therapy, a new challenge?
Bertrand Tombal
BJU International
|
February 25, 2012
New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist
Bertrand Tombal
European Urology
|
October 8, 2008
Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth
Bertrand Tombal
European Journal of Cancer (Oxford, England : 1990)
|
September 28, 2011
What is the pathophysiology of a hormone-resistant prostate tumour?
Bertrand Tombal
European Urology
|
September 24, 2011
Hormone therapy for prostate cancer: what have we done with Charles Huggins' legacy?
Bertrand Tombal
Urologia Internationalis
|
December 10, 2009
A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient
Bertrand Tombal
European Urology
|
August 9, 2012
Toward the end of blind prostate biopsies?
Bertrand Tombal
European Urology
|
December 18, 2013
Castration-resistant prostate cancer: adaptation or clonal selection? Insight from the EORTC 30891 trial
Bertrand Tombal
Page
of 32